AlzeCure Pharma
22.9.2021 14:20:11 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / September 22, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at the Naventus Life Science Summit at Grand Hotel in Stockholm on September 29 at 09:25 CEST, where CEO Martin Jönsson will present the company's latest developments.
The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq.
The presentation will be held in English and live streamed via https://events.naventus.com/ . The presentation will also be available after on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
AlzeCure presents at Naventus Life Science Summit on September 29
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/665112/AlzeCure-Presents-at-Naventus-Life-Science-Summit-on-September-29
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Announces Q3 2026 Results5.11.2026 14:25:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and nine months ended September 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTSThird quarter consolidated energy production totaled 175,791 MWh, a 3% decrease from 181,235 MWh in the same quarter last year. The decrease primarily reflected lower generation in the Dominican Republic and the Company's hydroelectric facilities in Peru and Ecuador, partially offset by stronger wind generation in Puerto Rico.The Company generated $19,005 in revenue from energy sales for the
Polaris Renewable Energy Declares Quarterly Dividend5.11.2026 14:20:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 20th, 2026, to shareholders of record at the close of business on November 12th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing and financially sound contributor to the energy transition.
Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook5.11.2026 14:15:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / November 5, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the third quarter of 2026, upward revision to 2026 outlook and full year 2027 outlook. "Our record results in the third quarter of 2026 reflects our continued successful execution along all our value drivers," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. "Most noteworthy our operating cash flow for the quarter after being reduced by our capital expenditures were a record for the quarter improving 46% over the comparative previous year period." Third Quarter 2026Net sales of $176.2 million, up 39.0% compared to the prior year's quarter.Net income of $19.6 million, compared to $27.6 million for the prior year's quarter.Diluted earnings per share of $0.20, compared to $0.29 for the prior year's quarter.Adjusted EBITDA of $71.9 million, up 46.5% compared to the pr
Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 174.11.2026 17:00:00 CET | Press release
SAN DIEGO, CA / ACCESS Newswire / November 4, 2026 / Blue Magic Ventures by General Atomics Aeronautical Systems, Inc. (GA-ASI) returns on November 17 for the next Blue Magic Netherlands (BMNL) Dual-Use Innovation & Investment Conference in Eindhoven. This is the third year that Netherlands-based technology companies have been invited to pitch innovative, transformative solutions addressing critical defense and security challenges. This year's event will feature remarks from key figures in the defense community: Brigadier General Peter Gielen, Military Advisor on Integrated Air and Missile Defence of the Netherlands; Mark Lengton, Deputy Commissioner Military Production, Ministry of Economic Affairs & Climate Policy; and Kadri Tammai, Chief Programme Officer, Regional Director, NATO DIANA (Defence Innovation Accelerator for the North Atlantic). "We've been successful in tapping into the Dutch ecosystem, which has a great wealth of knowledge and know-how," said Brad Lunn, managing direc
RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update4.11.2026 00:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 3, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQB:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce the launch of its fifth secured Green Bond offering, seeking to raise up to $5 million to support the continued growth of its renewable energy royalty portfolio. Building on the success of its previous Green Bond issuances, the Company will offer Series 5 secured Green Bond Units through a non-brokered private placement of Series 5 secured green bond units (the "Green Bond Units") at the price of either $1,000 or US$1,000 per Green Bond Unit for gross proceeds of up to $5,000,000 (the "Private Placement Offering"). Each Green Bond Unit will be comprised of $1,000 or US$1,000 principal amount of green bonds (the "Green Bonds") and 1,000 common share purchase warrants (each a "Warrant"). For the purposes of calculating the Private Placement Offering's aggregate gross proceeds, issuances of the United States dollar denominated Gree
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom